RBC Capital analyst Luke Davis maintains Parex Resources (TSX:PXT) with a Outperform and lowers the price target from C$38 to C$36.
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the